TY - JOUR
T1 - Management of chronic hepatitis B in special populations
T2 - Immunosuppressed patients and chronic kidney disease
AU - Fabrizi, Fabrizio
AU - Dixit, Vivek
AU - Messa, Piergiorgio
AU - Martin, Paul
PY - 2011/12
Y1 - 2011/12
N2 - Hepatitis B virus (HBV) infection remains an important cause of liver disease in the population with chronic kidney disease, including patients on long-term dialysis and renal transplant (RT) recipients. Diminished survival due to hepatitis B has been observed after RT. A thorough evaluation, including liver biopsy as well as assessment of serum markers of HBV replication (ie, hepatitis B e antigen and/or HBV DNA) is required before transplantation. Tolerance to interferon is poor both in dialysis patients and after renal transplant. Oral antiviral therapy now permits safe and potent antiviral treatment of HBV-related liver disease in chronic kidney disease patients with prevention of progressive liver disease. Preliminary evidence shows an improved survival of HBsAg positive renal allograft recipients on antiviral therapy. However, numerous issues concerning the treatment of hepatitis B in the population with chronic kidney disease remain unclear and further clinical trials are needed.
AB - Hepatitis B virus (HBV) infection remains an important cause of liver disease in the population with chronic kidney disease, including patients on long-term dialysis and renal transplant (RT) recipients. Diminished survival due to hepatitis B has been observed after RT. A thorough evaluation, including liver biopsy as well as assessment of serum markers of HBV replication (ie, hepatitis B e antigen and/or HBV DNA) is required before transplantation. Tolerance to interferon is poor both in dialysis patients and after renal transplant. Oral antiviral therapy now permits safe and potent antiviral treatment of HBV-related liver disease in chronic kidney disease patients with prevention of progressive liver disease. Preliminary evidence shows an improved survival of HBsAg positive renal allograft recipients on antiviral therapy. However, numerous issues concerning the treatment of hepatitis B in the population with chronic kidney disease remain unclear and further clinical trials are needed.
KW - Chronic kidney disease
KW - Hepatitis B Virus
KW - Immunosuppressive therapy
KW - Kidney transplantation
KW - Special populations
KW - Survival
UR - https://www.scopus.com/pages/publications/81355160499
U2 - 10.1007/s11901-011-0116-0
DO - 10.1007/s11901-011-0116-0
M3 - Article
AN - SCOPUS:81355160499
SN - 1540-3416
VL - 10
SP - 269
EP - 276
JO - Current Hepatitis Reports
JF - Current Hepatitis Reports
IS - 4
ER -